Keytruda: NICE Rejects English Funding For Endometrial Cancer But Says Yes For Renal Cancer
BMS's Onureg Also Wins Thumbs Up From NICE
Executive Summary
NICE has preliminarily rejected MSD’s drug for endometrial cancer in a decision that contrasts with that of its health technology assessment counterpart in Scotland.